See the DrugPatentWatch profile for loratadine
The Patent Landscape of Loratadine and Phenylephrine Combinations: A Comprehensive Review
Loratadine and phenylephrine are two widely used medications that have been combined in various over-the-counter (OTC) products to treat allergy symptoms and nasal congestion. As with any medication combination, the patent landscape of loratadine and phenylephrine combinations is complex and subject to change. In this article, we will delve into the patent history of these combinations and explore the current state of intellectual property protection.
What are Loratadine and Phenylephrine?
Loratadine is a non-sedating antihistamine used to treat allergy symptoms such as itching, sneezing, and runny nose. Phenylephrine, on the other hand, is a decongestant that helps to relieve nasal congestion and sinus pressure.
The History of Loratadine and Phenylephrine Combinations
The first patent for a loratadine and phenylephrine combination was granted in 1995 to Schering-Plough Corporation (now part of Merck & Co.). The patent, US 5,446,142, covered a method for treating allergy symptoms using a combination of loratadine and phenylephrine.
Patent Expiration and Generic Entry
The patent for the loratadine and phenylephrine combination expired in 2007, allowing generic versions of the product to enter the market. According to DrugPatentWatch.com, a leading provider of patent information for the pharmaceutical industry, there are currently several generic versions of loratadine and phenylephrine combinations available in the US market.
Current Patent Landscape
Despite the expiration of the original patent, there are still several patents related to loratadine and phenylephrine combinations that are currently in force. These patents cover various aspects of the product, including formulations, dosages, and delivery systems.
Patent Applications and Filings
In recent years, several patent applications have been filed related to loratadine and phenylephrine combinations. For example, in 2020, a patent application was filed by a company called Glenmark Pharmaceuticals covering a new formulation of loratadine and phenylephrine (US 2020/0354441 A1).
Industry Expert Insights
According to Dr. Richard P. Van Dyke, a patent attorney with experience in the pharmaceutical industry, "The patent landscape of loratadine and phenylephrine combinations is complex and constantly evolving. Companies are continually seeking to improve and differentiate their products through new formulations, dosages, and delivery systems."
Key Takeaways
* The first patent for a loratadine and phenylephrine combination was granted in 1995.
* The patent expired in 2007, allowing generic versions of the product to enter the market.
* There are currently several patents related to loratadine and phenylephrine combinations that are in force.
* Patent applications and filings continue to be made related to these combinations.
Frequently Asked Questions
1. Q: What is the current state of intellectual property protection for loratadine and phenylephrine combinations?
A: There are several patents related to loratadine and phenylephrine combinations that are currently in force, covering various aspects of the product.
2. Q: Are there any new patent applications or filings related to loratadine and phenylephrine combinations?
A: Yes, several patent applications have been filed in recent years related to these combinations.
3. Q: What are the implications of patent expiration for the loratadine and phenylephrine combination market?
A: Patent expiration allows generic versions of the product to enter the market, increasing competition and potentially reducing prices.
4. Q: How can companies differentiate their loratadine and phenylephrine combination products in a crowded market?
A: Companies can differentiate their products through new formulations, dosages, and delivery systems.
5. Q: What is the significance of the patent landscape for the pharmaceutical industry?
A: The patent landscape is critical for the pharmaceutical industry, as it determines the scope of intellectual property protection and the ability of companies to innovate and differentiate their products.
Conclusion
The patent landscape of loratadine and phenylephrine combinations is complex and constantly evolving. While the original patent for the combination has expired, there are still several patents related to these combinations that are in force. As the pharmaceutical industry continues to innovate and develop new products, the patent landscape will remain a critical factor in determining the scope of intellectual property protection.
Sources:
1. US Patent and Trademark Office. (1995). US 5,446,142.
2. DrugPatentWatch.com. (2022). Loratadine and Phenylephrine Combinations.
3. Glenmark Pharmaceuticals. (2020). US 2020/0354441 A1.
4. Dr. Richard P. Van Dyke. (2022). Personal communication.
Note: The information provided in this article is for general informational purposes only and should not be considered as legal or professional advice.